Founded in 1999, genOway is a global biotechnology company dedicated to the development
and commercialization of unique, innovative genetically modified mouse, rat and cell line
models for fundamental, preclinical and clinical research. Based on its core business and
leading expertise in custom-designed models, the company invests in cancer research, with a
growing catalog of currently over 30 translational models for immuno-oncology and
immunotherapy. genOway holds all relevant licenses on patented technologies used for its
model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9
patents portfolio, which enables the company to guarantee its clients FTO, freedom to
operate.
Headquartered in Lyon, France, genOway serves clients in 380 academic institutions and 170
life sciences companies, including 17 of the top 20 pharma.